About Index Trending news
Analyze
Pricing
AntriaBio

AntriaBio

AntriaBio

AntriaBio is developing proprietary products in sustained release injectable formulations including AB101, a once-a-week basal insulin. $ANTB

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO equity
$13,000,000
Medici Investment, Ildong Pharmaceutical, Aju Pharma
Post-IPO equity
$6,700,000
Employees

Team size

10+
Locations
$13,000,000 Post-IPO equity
BizWest

Pharmaceutical firm in Louisville raises $13 million

$6,700,000 Post-IPO equity
BizWest

AntriaBio raises $6.7M, plans to file new drug application

$7,000,000 Venture capital
Xconomy

Colorado Roundup: AntriaBio Raises $7M, VSCO Buys Artifact Uprising | Xconomy